RVMDRVMD
$172.3-2.3%11월 13일 종가 기준
시가총액 $37.3B
3달 전보다 -9.2%
최고 $221.15최저 $172.29
세로선 = 임상·딜 이벤트 · 차트 위에서 스크롤하면 확대·축소, 확대 중엔 가로로 넘겨볼 수 있어요
매수 의견AI 점수 85 / 100
RAS 유전자 변이가 원인인 고형암을 표적하는 저분자 정밀 항암제를 개발해요.
RVMD is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. They utilize structure-based drug discovery capabilities and proprietary technologies to create small molecules tailored to unconventional binding sites. Their precision medicine approaches inform innovative monotherapy and combination regimens.
진행 중인 임상과 AI 예측
- Phase 3전이성 췌장암 1차 치료 다락손라십 병용 1/2상 임상모집 중Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma37%
- Phase 3다락손라십(RMC-6236) RAS 변이 폐암 임상 3상모집 중Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)37%
- Phase 2RAS 저해제 및 이보네시맙 병용 고형암 치료 임상모집 중Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors72%
- Phase ?전이성 췌장암 치료제 다락손라십(RMC-6236) 동정적 사용 승인AVAILABLEExpanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma10%
- Phase 1RMC-5127 KRAS G12V 변이 고형암 임상모집 중Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors72%
- Phase 3졸돈라십 KRAS 변이 전이성 췌장암 1차 치료 3상 임상모집 중Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )38%
- Phase 3RMC-6236 췌장암 수술 후 보조요법 임상모집 중Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)33%
- Phase 2RAS 변이 폐암 표적 RAS(ON) 억제제 임상모집 중Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC73%
- Phase 1RMC-9805 KRAS 변이 고형암 치료 임상모집 중Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors78%
- Phase 3전이성 췌장암 대상 RMC-6236 3상 임상진행 중Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)57%
- Phase 2RMC-6236 RAS 변이 고형암 치료 임상모집 중Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS78%
- Phase 1RMC-6291 KRAS G12C 변이 고형암 단독투여 임상진행 중Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors72%
성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.